Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics Lexeo Therapeutics (Nasdaq: LXEO) announced multiple senior leadership appointments and an update to its strategic partnership for cardiac RNA therapeutics on January 27, 2026. Key hires include Narinder Bhalla, MD as Chief Medical Officer, José Manuel Otero, PhD as Chief Operating Officer, and new cardiology development leads Hayes Dansky, MD and Greg Aubert, MD, PhD. Eric Adler, MD will become CEO of Myoventive, a cardiac precision medicines company co-founded by Lexeo and partners to develop a novel non-viral RNA platform for genetic cardiac diseases. The appointments are presented as strengthening late-stage clinical and commercial execution while maintaining discovery and early cardiac development.

#LXEO Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

www.stocktitan.net/news/LXEO/lexeo-therapeu...

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy Lexeo Therapeutics (NASDAQ: LXEO) reported interim Phase I/II HEROIC-PKP2 data for LX2020 in PKP2-associated arrhythmogenic cardiomyopathy on Jan 12, 2026.Ten participants dosed 13 vg/kg, high 6x1013 vg/kg). LX2020 was generally well tolerated, no clinically significant complement activation, and all LFT elevations resolved with protocol immunosuppression. In biopsies (n=7) mean PKP2 protein increased +93%

#LXEO Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

www.stocktitan.net/news/LXEO/lexeo-therapeu...

🚨 Institutions #optionsvolume surge detected! Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.

🚨 Institutions #optionsvolume surge detected!

Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #GTES 486.0x
2. #DDD 339.4x
3. #EWCZ 267.6x
4. #HSAI 130.4x
5. #LXEO 126.6x

#OptionFlow #OptionsTrading #Trading

Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights Lexeo Therapeutics (NASDAQ:LXEO) reported Q3 2025 results and program updates on Nov 5, 2025. Key clinical and corporate highlights include FDA acceptance to pool Phase I/II LX2006 data with pivotal data for a potential BLA path, and FDA approval in November 2025 of an analytical comparability report endorsing the Sf9 commercial manufacturing process for LX2006. Interim LX2006 data show 18% LVMI improvement at 6 months, 23% at 12 months (n=6 with abnormal baseline), and a 2.0-point mean mFARS improvement (n=16). Lexeo closed a $154 million equity financing in October 2025; Q3 cash was $122.8M (pre-proceeds), and proceeds are expected to fund operations into 2028.

#LXEO Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

www.stocktitan.net/news/LXEO/lexeo-therapeu...

Leading Indicators, Thursday October 23, 2025 – Crystal Equity Research

Small-cap stocks overbought with declining relative strength, Thu Oct 23rd - #LXEO #GSIT - More: crystalequityresearch.com/leading-indi... - #smallcap

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that it has priced its underwritten public offering and concurrent private placement

#LXEO Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

www.stocktitan.net/news/LXEO/lexeo-therapeu...

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants Lexeo Therapeutics (Nasdaq: LXEO) announced on October 16, 2025 that it commenced an underwritten public offering and a concurrent private placement of common stock and, for certain investors, pre-funded warrants to purchase common stock.The company said it will grant underwriters a 30-day option to buy additional shares, named joint book-runners and stated the offering is being made under a Form S-3 registration statement declared effective by the SEC. The offering and private placement are subject to market and customary conditions and may not be completed.

#LXEO Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/LXEO/lexeo-therapeu...

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $17 Price Target from Chardan Capital

#LXEO 📈📉 www.stocks2buynow.com/newsitems/le...

PRISM Morning Movers:
Top Gainers:
#Galecto, Inc. ( #GLTO) - up 726%
#C3is Inc. ( #CISS) - up 55%
#SpruceBiosciences, Inc. ( #SPRB) - up 41%
#LexeoTherapeutics, Inc. ( #LXEO) - up 32%
Top Decliners:
#SocietyPass Incorporated ( #SOPA) - down 25%
#SANUWAVE Health, Inc. ( #SNWV) - down 18%

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval Interim clinical data show sustained or deepening improvements in the majority of participants across

#LXEO Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

www.stocktitan.net/news/LXEO/lexeo-therapeu...

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights Lexeo Therapeutics (NASDAQ:LXEO) reported significant Q2 2025 developments and financial results. The company received FDA Breakthrough Therapy designation for LX2006 for Friedreich ataxia treatment, demonstrating meaningful cardiac and neurologic improvements. Eight participants were dosed in the Phase I/II HEROIC-PKP2 trial of LX2020 for PKP2-ACM.The company secured an $80 million equity financing and ended Q2 with $152.5 million in cash and equivalents, extending runway into 2028. Lexeo also formed a strategic partnership with Perceptive Xontogeny Venture Funds and venBio Partners for RNA-based cardiac therapies, and appointed Louis Tamayo as CFO. Q2 net loss was $26.1 million ($0.60 per share) compared to $21.2 million ($0.64 per share) in Q2 2024.

#LXEO Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

www.stocktitan.net/news/LXEO/lexeo-therapeu...

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia Lexeo Therapeutics (Nasdaq: LXEO) has achieved a significant milestone as its drug candidate LX2006 received FDA Breakthrough Therapy designation for treating Friedreich ataxia (FA). The designation was based on promising interim clinical data from Phase I/II trials showing meaningful improvements in cardiac biomarkers and functional measures.The drug has demonstrated clinically significant improvements in cardiac and neurologic functional measures, with increased frataxin expression observed in all cardiac biopsy participants at three months post-treatment. To date, 17 participants have been treated across two trials. The company plans to initiate a registrational study by early 2026.Additionally, LX2006 has been selected for the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, aimed at facilitating faster patient access to promising therapies.

#LXEO Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

www.stocktitan.net/news/LXEO/lexeo-therapeu...

Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics Lexeo Therapeutics (NASDAQ:LXEO) has announced a strategic partnership to develop novel RNA-based therapeutics for genetic cardiac diseases through a new entity backed by up to $40 million in private equity financing from Perceptive Xontogeny Venture Funds and venBio Partners.The new venture will combine Lexeo's expertise in cardiac genetic medicines with a novel non-viral RNA delivery platform. Lexeo will receive a double-digit percentage equity stake, milestone payments, royalties, and opt-in rights to certain programs. The genetic and precision cardiology market is projected to grow from $13 billion in 2025 to nearly $40 billion by 2033.

#LXEO Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

www.stocktitan.net/news/LXEO/lexeo-therapeu...

Major Investors Back Lexeo Therapeutics with $80M for Breakthrough Genetic Heart Disease Programs New financing extends runway to 2028, accelerating development of genetic medicines for heart diseases. Led by Frazier Life Sciences and Janus Henderson. See development timeline.

#LXEO Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

www.stocktitan.net/news/LXEO/lexeo-therapeu...

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights Lexeo Therapeutics (NASDAQ: LXEO) reported Q1 2025 financial results and operational updates. The company announced positive interim data for LX2006 in Friederich ataxia cardiomyopathy, with frataxin expression and LVMI improvements exceeding target thresholds. The high-dose cohort showed a 115% increase in cardiac frataxin expression and a 25% mean reduction in LVMI. Lexeo plans to initiate a registrational study by early 2026. For LX2020 in PKP2-ACM, interim data showed promising results with 71-115% increases in PKP2 protein expression. The company reported cash position of $106.9 million, redeployed $20 million to clinical programs, and implemented a 15% workforce reduction. Q1 2025 net loss was $32.7 million ($0.99/share) compared to $21.7 million ($0.77/share) in Q1 2024.

#LXEO Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

www.stocktitan.net/news/LXEO/lexeo-therapeu...

Breakthrough Data: Gene Therapy Shows 25% Heart Improvement in Fatal Rare Disease New gene therapy achieves 25% cardiac improvement in Friedreich ataxia patients. Strong safety profile supports advancement to final testing phase. Full analysis inside.

#LXEO Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

www.stocktitan.net/news/LXEO/lexeo-therapeu...

NEWS: ( NASDAQ: #LXEO ) Expected US Company Earnings on Monday, March 24th, 2025

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights Lexeo Therapeutics (NASDAQ: LXEO) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its gene therapy programs. The company achieved further FDA alignment on LX2006's pivotal study for Friedreich ataxia cardiomyopathy, with protein expression to be evaluated for any increase from baseline.Early data from the LX2020 HEROIC-PKP2 Phase 1/2 trial showed promising results, with 71% and 115% increases in PKP2 protein expression in the first two post-treatment biopsies. The first participant demonstrated a 67% reduction in premature ventricular contractions after 6 months.Financial highlights include:Cash position of $128.5 million, providing runway into 2027Q4 2024 R&D expenses of $18.4 million vs $8.2 million in Q4 2023Q4 2024 net loss of $25.9 million ($0.78 per share)Full-year 2024 net loss of $98.3 million ($3.09 per share)

#LXEO Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

www.stocktitan.net/news/LXEO/lexeo-therapeu...

NEWS: ( NASDAQ: #LXEO ) Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

#StockMarket #News